Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

Stock Information for 22nd Century Group Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About 22nd Century Group Inc

Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results
Vaxart to Host Upcoming Conference Calls
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025
Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025
Vaxart Announces Withdrawal of Reverse Stock Split Proposal
Concerned Vaxart Stockholders Respond to Inadequate Governance Announcements

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.